The effect of high dehydroepiandrosterone sulfate levels on tamoxifen blockade and breast cancer progression

American Journal of Surgery

Volumn 185, Issue 5, 2003, Pages 411-415

  Calhoun, Kristine ^a   Pommier, Rodney ^a   Cheek, Julie ^a   Fletcher, William ^a   Toth Fejel, SuEllen ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Breast cancer; DHEA S; Tamoxifen

Indexed keywords

PRASTERONE SULFATE; SEX HORMONE; TAMOXIFEN;

ADULT; ANTINEOPLASTIC ACTIVITY; BREAST CARCINOMA; CALCULATION; CALORIMETRY; CANCER CELL; CANCER GROWTH; CANCER INHIBITION; CANCER PATIENT; CELL STIMULATION; CONFERENCE PAPER; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; FOLLOW UP; HORMONE BLOOD LEVEL; HUMAN; HUMAN CELL; IN VITRO STUDY; MAJOR CLINICAL STUDY; METASTASIS; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME;

ADULT; AGE FACTORS; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CELL DIVISION; DEHYDROEPIANDROSTERONE SULFATE; DISEASE PROGRESSION; DRUG RESISTANCE; ESTROGEN ANTAGONISTS; FEMALE; GONADAL STEROID HORMONES; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; RECEPTORS, ESTROGEN; RETROSPECTIVE STUDIES; RISK FACTORS; TAMOXIFEN; TUMOR CELLS, CULTURED;

EID: 0037406646     PISSN: 00029610     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9610(03)00054-0     Document Type: Article

References (14)

1. Jaiyesimi I.A., Buzdar A.U., Decker D.A., Hortobagyi G.N. Use of tamoxifen for breast cancer twenty-eight years later. J Clin Oncol. 13:1995;513-529.
2. Pharmacokinetics of anastrozole and tamoxifen alone, and in combination, during adjuvant endocrine therapy for early breast cancer in post-menopausal women a sub-protocol of the Arimidex and Tamoxifen Alone or in Combination (ATAC) trial. Br J Cancer. 85:2001;317-324.
3. Tamoxifen for early breast cancer an overview of the randomized trials. Lancet. 351:1998;1451-1467.
4. Fisher B., Costantino J.P., Wickerham D.L., et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst. 90:1998;1371-1388.
5. Rutqvist L.E., Johansson H., Signomklao T., et al. Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies. J Natl Cancer Inst. 87:1995;645-651.
6. Kroboth P.D., Salek F.S., Pittenger A.L., et al. DHEA and DHEA-S a review. J Clin Pharmacol. 39:1999;327-348.
7. Barrett-Connor E., Friedlander N.J., Khaw K. Dehydroepiandrosterone sulfate and breast cancer risk. Cancer Res. 50:1990;6571-6574.
8. Morris K.T., Toth-Fejel S., Schmidt J., et al. High DHEA-sulfate predicts breast cancer progression during new aromatase inhibitor therapy and stimulates breast cancer cell growth in tissue culture a renewed role for adrenalectomy. Surgery. 130:2001;947-953.
9. Mosmann T. Rapid colorimetric assay for cellular growth and survival application to proliferation and cytotoxicity assays. J Immunolog Meth. 65:1983;55-63.
10. Nixon A.J., Neuberg D., Hayes D.F., et al. Relationship of patient age to pathologic features of the tumor and prognosis for patients with stage I or II breast cancer. J Clin Oncol. 12:1994;88.
11. Albain K.S., Allred D.C., Clark G.M. Breast cancer outcome and predictors of outcome are there age differentials? J Nat Cancer Inst. 16:1994;35.
12. Wolf D.M., Langan-Fahey S.M., Parker C.J., et al. Investigation of the mechanism of tamoxifen-stimulated breast tumor growth with nonisomerizable analogues of tamoxifen and metabolites. J Nat Cancer Inst. 85:1993;806-812.
13. Favoni R.E., de Cupis A. Steroidal and nonsteroidal oestrogen antagonist in breast cancer: basic and clinical appraisal. Trends in Pharmacological Sciences. 19:1998;406-415.
14. MacCallum J., Cummings J., Dixon J.M., Miller W.R. Concentrations of tamoxifen and its major metabolites in hormone responsive and resistant breast tumors. Br J Cancer. 82:2000;1629-1635.